{
    "address1": "251 Ballardvale Street",
    "city": "Wilmington",
    "state": "MA",
    "zip": "01887",
    "country": "United States",
    "phone": "781 222 6000",
    "website": "https://www.criver.com",
    "industry": "Diagnostics & Research",
    "industryKey": "diagnostics-research",
    "industryDisp": "Diagnostics & Research",
    "sector": "Healthcare",
    "sectorKey": "healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug  discovery and  development. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.",
    "fullTimeEmployees": 18700,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Mr. James C. Foster J.D.",
            "age": 73,
            "title": "Chairman, President & CEO",
            "yearBorn": 1951,
            "fiscalYear": 2024,
            "totalPay": 2246975,
            "exercisedValue": 1392962,
            "unexercisedValue": 141941
        },
        {
            "maxAge": 1,
            "name": "Ms. Birgit  Girshick",
            "age": 54,
            "title": "Corporate Executive VP & COO",
            "yearBorn": 1970,
            "fiscalYear": 2024,
            "totalPay": 1102643,
            "exercisedValue": 405069,
            "unexercisedValue": 32110
        },
        {
            "maxAge": 1,
            "name": "Mr. Joseph W. LaPlume J.D.",
            "age": 50,
            "title": "Corporate Executive Vice President of Corporate Development & Strategy",
            "yearBorn": 1974,
            "fiscalYear": 2024,
            "totalPay": 806426,
            "exercisedValue": 0,
            "unexercisedValue": 33024
        },
        {
            "maxAge": 1,
            "name": "Ms. Victoria L. Creamer",
            "age": 54,
            "title": "Corporate Executive VP & Chief People Officer",
            "yearBorn": 1970,
            "fiscalYear": 2024,
            "totalPay": 780419,
            "exercisedValue": 0,
            "unexercisedValue": 20644
        },
        {
            "maxAge": 1,
            "name": "Mr. Michael Gunnar Knell",
            "age": 47,
            "title": "Interim CFO, Corporate Senior VP & Chief Accounting Officer",
            "yearBorn": 1977,
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Prof. Julie  Frearson Ph.D.",
            "title": "Corporate Senior VP & Chief Scientific Officer",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Mark  Mintz",
            "title": "Corporate EVP, Chief Information Officer & Global Shared Services",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Todd  Spencer",
            "title": "Corporate Vice President of Investor Relations",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Matthew L. Daniel J.D.",
            "title": "Corporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Amy E. Cianciaruso",
            "title": "Corporate Senior Vice President, Chief Communications Officer & Government Relations",
            "fiscalYear": 2024,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 2,
    "boardRisk": 7,
    "compensationRisk": 8,
    "shareHolderRightsRisk": 8,
    "overallRisk": 8,
    "governanceEpochDate": 1761955200,
    "compensationAsOfEpochDate": 1735603200,
    "irWebsite": "http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-irhome",
    "executiveTeam": [],
    "maxAge": 86400,
    "priceHint": 2,
    "previousClose": 179.11,
    "open": 178.39,
    "dayLow": 178.17,
    "dayHigh": 181.56,
    "regularMarketPreviousClose": 179.11,
    "regularMarketOpen": 178.39,
    "regularMarketDayLow": 178.17,
    "regularMarketDayHigh": 181.56,
    "payoutRatio": 0.0,
    "beta": 1.503,
    "forwardPE": 17.516539,
    "volume": 950211,
    "regularMarketVolume": 950211,
    "averageVolume": 970421,
    "averageVolume10days": 1142460,
    "averageDailyVolume10Day": 1142460,
    "bid": 176.05,
    "ask": 184.45,
    "bidSize": 2,
    "askSize": 1,
    "marketCap": 8861997056,
    "fiftyTwoWeekLow": 91.86,
    "fiftyTwoWeekHigh": 230.02,
    "allTimeHigh": 460.21,
    "allTimeLow": 17.1875,
    "priceToSalesTrailing12Months": 2.1997628,
    "fiftyDayAverage": 167.0006,
    "twoHundredDayAverage": 154.7185,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "tradeable": false,
    "enterpriseValue": 11514407936,
    "profitMargins": -0.01664,
    "floatShares": 48622624,
    "sharesOutstanding": 49214178,
    "sharesShort": 2087410,
    "sharesShortPriorMonth": 2563173,
    "sharesShortPreviousMonthDate": 1757894400,
    "dateShortInterest": 1760486400,
    "sharesPercentSharesOut": 0.0424,
    "heldPercentInsiders": 0.01002,
    "heldPercentInstitutions": 1.05239,
    "shortRatio": 2.22,
    "shortPercentOfFloat": 0.048800003,
    "impliedSharesOutstanding": 49214178,
    "bookValue": 68.144,
    "priceToBook": 2.6424925,
    "lastFiscalYearEnd": 1735344000,
    "nextFiscalYearEnd": 1766880000,
    "mostRecentQuarter": 1751068800,
    "earningsQuarterlyGrowth": -0.444,
    "netIncomeToCommon": -69225000,
    "trailingEps": -1.3,
    "forwardEps": 10.28,
    "enterpriseToRevenue": 2.858,
    "enterpriseToEbitda": 12.048,
    "52WeekChange": -0.013206899,
    "SandP52WeekChange": 0.19736934,
    "quoteType": "EQUITY",
    "currentPrice": 180.07,
    "targetHighPrice": 211.0,
    "targetLowPrice": 155.0,
    "targetMeanPrice": 186.86667,
    "targetMedianPrice": 195.0,
    "recommendationMean": 2.16667,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 15,
    "totalCash": 182824000,
    "totalCashPerShare": 3.715,
    "ebitda": 955694016,
    "totalDebt": 2788969984,
    "quickRatio": 0.88,
    "currentRatio": 1.36,
    "totalRevenue": 4028614912,
    "debtToEquity": 82.039,
    "revenuePerShare": 79.633,
    "returnOnAssets": 0.043109998,
    "returnOnEquity": -0.01809,
    "grossProfits": 1411084032,
    "freeCashflow": 706380992,
    "operatingCashflow": 787454016,
    "earningsGrowth": -0.391,
    "revenueGrowth": 0.006,
    "grossMargins": 0.35027,
    "ebitdaMargins": 0.23723,
    "operatingMargins": 0.16668,
    "financialCurrency": "USD",
    "symbol": "CRL",
    "language": "en-US",
    "region": "US",
    "typeDisp": "Equity",
    "quoteSourceName": "Delayed Quote",
    "triggerable": true,
    "customPriceAlertConfidence": "HIGH",
    "postMarketChangePercent": 0.51646173,
    "postMarketPrice": 181.0,
    "postMarketChange": 0.9299927,
    "regularMarketChange": 0.960007,
    "regularMarketDayRange": "178.17 - 181.56",
    "fullExchangeName": "NYSE",
    "averageDailyVolume3Month": 970421,
    "hasPrePostMarketData": true,
    "firstTradeDateMilliseconds": 961767000000,
    "fiftyTwoWeekLowChange": 88.21001,
    "fiftyTwoWeekLowChangePercent": 0.9602657,
    "fiftyTwoWeekRange": "91.86 - 230.02",
    "fiftyTwoWeekHighChange": -49.949997,
    "fiftyTwoWeekHighChangePercent": -0.21715501,
    "fiftyTwoWeekChangePercent": -1.3206899,
    "earningsTimestamp": 1762349400,
    "earningsTimestampStart": 1762349400,
    "earningsTimestampEnd": 1762349400,
    "earningsCallTimestampStart": 1762351200,
    "earningsCallTimestampEnd": 1762351200,
    "isEarningsDateEstimate": false,
    "epsTrailingTwelveMonths": -1.3,
    "epsForward": 10.28,
    "epsCurrentYear": 10.18992,
    "priceEpsCurrentYear": 17.671385,
    "fiftyDayAverageChange": 13.069412,
    "fiftyDayAverageChangePercent": 0.07825968,
    "twoHundredDayAverageChange": 25.351501,
    "twoHundredDayAverageChangePercent": 0.16385566,
    "sourceInterval": 15,
    "exchangeDataDelayedBy": 0,
    "averageAnalystRating": "2.2 - Buy",
    "cryptoTradeable": false,
    "corporateActions": [],
    "postMarketTime": 1761954781,
    "regularMarketTime": 1761940802,
    "exchange": "NYQ",
    "messageBoardId": "finmb_91093",
    "exchangeTimezoneName": "America/New_York",
    "exchangeTimezoneShortName": "EST",
    "gmtOffSetMilliseconds": -18000000,
    "market": "us_market",
    "esgPopulated": false,
    "regularMarketChangePercent": 0.535987,
    "regularMarketPrice": 180.07,
    "marketState": "CLOSED",
    "shortName": "Charles River Laboratories Inte",
    "longName": "Charles River Laboratories International, Inc.",
    "displayName": "Charles River Laboratories",
    "trailingPegRatio": 0.1339
}